- Home
- JCI vs EW Comparison
JCI vs EW Comparison
Compare JCI & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCI
- EW
- Stock Information
- Founded
- JCI 1885
- EW 1958
- Country
- JCI Ireland
- EW United States
- Employees
- JCI N/A
- EW N/A
- Industry
- JCI Industrial Machinery/Components
- EW Industrial Specialties
- Sector
- JCI Industrials
- EW Health Care
- Exchange
- JCI Nasdaq
- EW Nasdaq
- Market Cap
- JCI 49.1B
- EW 40.7B
- IPO Year
- JCI N/A
- EW 2000
- Fundamental
- Price
- JCI $91.24
- EW $74.61
- Analyst Decision
- JCI Buy
- EW Buy
- Analyst Count
- JCI 13
- EW 20
- Target Price
- JCI $91.46
- EW $79.45
- AVG Volume (30 Days)
- JCI 4.4M
- EW 4.6M
- Earning Date
- JCI 05-07-2025
- EW 04-23-2025
- Dividend Yield
- JCI 1.65%
- EW N/A
- EPS Growth
- JCI 45.88
- EW 201.77
- EPS
- JCI 3.62
- EW 7.02
- Revenue
- JCI $23,248,000,000.00
- EW $5,522,300,000.00
- Revenue This Year
- JCI $2.86
- EW $10.07
- Revenue Next Year
- JCI $4.65
- EW $9.65
- P/E Ratio
- JCI $24.77
- EW $10.70
- Revenue Growth
- JCI 8.21
- EW N/A
- 52 Week Low
- JCI $64.31
- EW $58.93
- 52 Week High
- JCI $92.41
- EW $95.25
- Technical
- Relative Strength Index (RSI)
- JCI 71.13
- EW 56.61
- Support Level
- JCI $87.77
- EW $74.25
- Resistance Level
- JCI $89.49
- EW $77.12
- Average True Range (ATR)
- JCI 2.20
- EW 1.85
- MACD
- JCI 1.32
- EW 0.11
- Stochastic Oscillator
- JCI 93.80
- EW 70.44
About JCI Johnson Controls International plc
Johnson Controls manufactures, installs, and services commercial HVAC systems, building management platforms and controls, fire and security solutions, and industrial refrigeration units. Commercial HVAC and fire and security each account for approximately 45% of sales, while industrial refrigeration and other solutions account for the remaining 10% of revenue. In fiscal 2024, Johnson Controls generated nearly $23 billion in pro forma revenue.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.